These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 10356365)
41. Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer. LoPiccolo J; Kim SJ; Shi Y; Wu B; Wu H; Chait BT; Singer RH; Sali A; Brenowitz M; Bresnick AR; Backer JM J Biol Chem; 2015 Dec; 290(51):30390-405. PubMed ID: 26475863 [TBL] [Abstract][Full Text] [Related]
42. The structure of p85ni in class IA phosphoinositide 3-kinase exhibits interdomain disorder. Sen KI; Wu H; Backer JM; Gerfen GJ Biochemistry; 2010 Mar; 49(10):2159-66. PubMed ID: 20131869 [TBL] [Abstract][Full Text] [Related]
43. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα. Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266 [TBL] [Abstract][Full Text] [Related]
45. Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation. Mellor P; Marshall JDS; Ruan X; Whitecross DE; Ross RL; Knowles MA; Moore SA; Anderson DH Sci Rep; 2018 May; 8(1):7108. PubMed ID: 29740032 [TBL] [Abstract][Full Text] [Related]
46. Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα. Hart JR; Liu X; Pan C; Liang A; Ueno L; Xu Y; Quezada A; Zou X; Yang S; Zhou Q; Schoonooghe S; Hassanzadeh-Ghassabeh G; Xia T; Shui W; Yang D; Vogt PK; Wang MW Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2210769119. PubMed ID: 36095215 [TBL] [Abstract][Full Text] [Related]
47. Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα). Vogt PK; Hart JR; Yang S; Zhou Q; Yang D; Wang MW Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188947. PubMed ID: 37394020 [TBL] [Abstract][Full Text] [Related]
48. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation. Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156 [TBL] [Abstract][Full Text] [Related]
49. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations. Chakrabarti M; Gabelli SB; Amzel LM Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032 [TBL] [Abstract][Full Text] [Related]
50. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Sun M; Hart JR; Hillmann P; Gymnopoulos M; Vogt PK Cell Cycle; 2011 Nov; 10(21):3731-9. PubMed ID: 22045127 [TBL] [Abstract][Full Text] [Related]
51. Enzyme Is the Name-Adapter Is the Game. Huber M; Brummer T Cells; 2024 Jul; 13(15):. PubMed ID: 39120280 [TBL] [Abstract][Full Text] [Related]
52. Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight. Sharma J; Bhardwaj V; Purohit R ACS Omega; 2019 Oct; 4(14):15815-15823. PubMed ID: 31592171 [TBL] [Abstract][Full Text] [Related]
53. Correction for Taniguchi et al., Phosphoinositide 3-kinase regulatory subunit p85α suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci U S A; 2016 Jun; 113(25):E3588. PubMed ID: 27330087 [No Abstract] [Full Text] [Related]
54. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Bi L; Okabe I; Bernard DJ; Nussbaum RL Mamm Genome; 2002 Mar; 13(3):169-72. PubMed ID: 11919689 [No Abstract] [Full Text] [Related]
56. Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. Ueki K; Fruman DA; Yballe CM; Fasshauer M; Klein J; Asano T; Cantley LC; Kahn CR J Biol Chem; 2017 Mar; 292(13):5608. PubMed ID: 28363934 [No Abstract] [Full Text] [Related]
57. Correction: Lipid signaling to membrane proteins: From second messengers to membrane domains and adapter-free endocytosis. Hilgemann DW; Dai G; Collins A; Lariccia V; Magi S; Deisl C; Fine M J Gen Physiol; 2018 Feb; 150(2):367. PubMed ID: 29339379 [No Abstract] [Full Text] [Related]
58. Correction: ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer. Lim EJ; Kang JH; Kim YJ; Kim S; Lee SJ Cell Death Dis; 2022 Nov; 13(11):968. PubMed ID: 36400751 [No Abstract] [Full Text] [Related]